gemcitabine has been researched along with deoxyglucose in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Altmann, A; Bellemann, ME; Blatter, J; Haberkorn, U; Kahn, B; Morr, I; Oberdorfer, F; van Kaick, G | 1 |
| Altmann, A; Bellemann, ME; Blatter, J; Brix, G; Doll, J; Gerlach, L; Haberkorn, U; Morr, I; Oberdorfer, F; van Kaick, G | 1 |
| Beasley, TM; Boothman, DA; Buchsbaum, DJ; Kim, H; Lee, SK; Li, LS; Martin, A; Rigell, CJ; Samuel, SL; Stockard, CR; Umphrey, HR; Zhai, G; Zinn, KR | 1 |
| Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J | 1 |
| Bruno, S; Butera, G; Conti, P; Donadelli, M; Margiotta, M; Mullappilly, N; Pacchiana, R; Riganti, C | 1 |
| Chen, Q; Dai, S; Hou, C; Liu, T; Miao, Y; Peng, Y; Wu, J; Xu, D; Xu, W; Zhu, F; Zhu, X; Zhu, Y | 1 |
6 other study(ies) available for gemcitabine and deoxyglucose
| Article | Year |
|---|---|
Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyglucose; Fluorodeoxyglucose F18; Gemcitabine; In Vitro Techniques; Male; Prostatic Neoplasms; Rats; Tomography, Emission-Computed; Tumor Cells, Cultured | 1994 |
PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; Deoxyglucose; DNA, Neoplasm; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Male; Neoplasm Transplantation; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Ribonucleotide Reductases; Thymidine; Tomography, Emission-Computed; Tritium; Tumor Cells, Cultured | 1997 |
Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.
Topics: Animals; Antibodies, Neoplasm; Basigin; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Drug Delivery Systems; Female; Gemcitabine; Mice; Pancreatic Neoplasms; Positron-Emission Tomography; Tumor Burden | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Doxorubicin; Energy Metabolism; Gemcitabine; Glycolysis; Humans; Hydrogen; Metformin; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2014 |
Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.
Topics: AMP-Activated Protein Kinase Kinases; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Cytosol; Deoxycytidine; Deoxyglucose; Gemcitabine; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Mutation; Pancreatic Neoplasms; Protein Kinases; Protein Transport; Signal Transduction; Sirtuin 1; Tumor Suppressor Protein p53 | 2018 |
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Topics: Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Mice; Mice, Inbred BALB C; Pancreas; Pancreatic Neoplasms; Prognosis | 2020 |